--(BUSINESS WIRE)--NeurOp, Inc. is an Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including depression, neuropathic pain, ischemia (stroke), schizophrenia, and Alzheimer’s and Parkinson’s diseases. Its research targets various subunits of neuronal NMDA receptors and their potential therapeutic benefit. The company has licensed its technology to Bristol-Myers Squibb for the development of a compound for treatment-resistant depression. Multi-year funding from the NIH supports NeurOp's research and development programs for schizophrenia, Alzheimer’s disease and NP10679, its drug candidate for the prevention of ischemic damage during a stroke or subarachnoid hemorrhage. For more information, please visit www.neuropinc.com or follow us on LinkedIn.
Company: |
NeurOp, Inc. | |||||
Headquarters Address: |
58 Edgewood Ave., NE | |||||
Atlanta, GA 30303 | ||||||
Main Telephone: |
9192605595 | |||||
Website: |
||||||
Type of Organization: |
Private | |||||
Industry: |
Biotechnology | |||||
Key Executives: |
CEO: Barney Koszalka |
|||||
Public Relations |
||||||
Contact: |
Robin Fastenau | |||||
Phone: |
9193499824 |